Gilead Sciences Inc.’s submission of its HIV therapy elvitegravir to FDA, announced late June 27, could mean the beginning of competition in the integrase inhibitor field – and offer the first once-daily option.
Elvitegravir initially was developed by Japan Tobacco Inc., which licensed worldwide rights to Gilead in 2005. The drug, at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?